DAMPs and neurodegeneration

Ageing Research Reviews

Volumn 24, Issue , 2015, Pages 17-28

  Thundyil, John ^a   Lim, Kah Leong ^a,b,c  

^a NATIONAL NEUROSCIENCE INSTITUTE   (Singapore)

^b DUKE NUS MEDICAL SCHOOL   (Singapore)

^c NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

DAMPs; Inflammasomes; Neurodegeneration; Neuroinflammation; PRRs

Indexed keywords

ADENOSINE TRIPHOSPHATE; ADVANCED GLYCATION END PRODUCT RECEPTOR; ALPHA SYNUCLEIN; BECLIN 1; CRYOPYRIN; HEAT SHOCK PROTEIN; HIGH MOBILITY GROUP B1 PROTEIN; INFLAMMASOME; INTERLEUKIN 1BETA; MITOCHONDRIAL DNA; NUCLEOTIDE BINDING OLIGOMERIZATION DOMAIN LIKE RECEPTOR; PROTEIN S100B; TOLL LIKE RECEPTOR; TOLL LIKE RECEPTOR 4; URIC ACID;

ALZHEIMER DISEASE; CENTRAL NERVOUS SYSTEM; HUMAN; HUNTINGTON CHOREA; INFLAMMATION; INNATE IMMUNITY; NERVE DEGENERATION; NONHUMAN; OLIGOMERIZATION; PARKINSON DISEASE; REVIEW; AGING; ANIMAL; DEGENERATIVE DISEASE; IMMUNOLOGY; METABOLISM; PATHOLOGY;

AGING; ANIMALS; HUMANS; INFLAMMASOMES; NEURODEGENERATIVE DISEASES;

EID: 84946830786     PISSN: 15681637     EISSN: 18729649     Source Type: Journal    
DOI: 10.1016/j.arr.2014.11.003     Document Type: Review

References (151)

1. Adachi H., Katsuno M., Waza M., Minamiyama M., Tanaka F., Sobue G. Heat shock proteins in neurodegenerative diseases: pathogenic roles and therapeutic implications. Int. J. Hyperther 2009, 25:647-654. (the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group).
2. Alonso A., Rodriguez L.A., Logroscino G., Hernan M.A. Gout and risk of Parkinson disease: a prospective study. Neurology 2007, 69:1696-1700.
3. Alonso A., Sovell K.A. Gout, hyperuricemia, and Parkinson's disease: a protective effect?. Curr. Rheumatol. Rep. 2010, 12:149-155.
4. Amor S., Puentes F., Baker D., van der Valk P. Inflammation in neurodegenerative diseases. Immunology 2010, 129:154-169.
5. Andreadou E., Nikolaou C., Gournaras F., Rentzos M., Boufidou F., Tsoutsou A., Zournas C., Zissimopoulos V., Vassilopoulos D. Serum uric acid levels in patients with Parkinson's disease: their relationship to treatment and disease duration. Clin. Neurol. Neurosurg. 2009, 111:724-728.
6. Annanmaki T., Muuronen A., Murros K. Low plasma uric acid level in Parkinson's disease. Mov. Disord. 2007, 22:1133-1137.
7. Annanmaki T., Pessala-Driver A., Hokkanen L., Murros K. Uric acid associates with cognition in Parkinson's disease. Parkinsonism Relat. Disord. 2008, 14:576-578.
8. Annanmaki T., Pohja M., Parviainen T., Hakkinen P., Murros K. Uric acid and cognition in Parkinson's disease: a follow-up study. Parkinson. Relat. Disord. 2011, 17:333-337.
9. Apelt J., Schliebs R. Beta-amyloid-induced glial expression of both pro- and anti-inflammatory cytokines in cerebral cortex of aged transgenic Tg2576 mice with Alzheimer plaque pathology. Brain Res. 2001, 894:21-30.
10. Arroyo D.S., Soria J.A., Gaviglio E.A., Rodriguez-Galan M.C., Iribarren P. Toll-like receptors are key players in neurodegeneration. Int. Immunopharmacol. 2011, 11:1415-1421.
11. Arumugam T.V., Okun E., Tang S.C., Thundyil J., Taylor S.M., Woodruff T.M. Toll-like receptors in ischemia-reperfusion injury. Shock 2009, 32:4-16.
12. Auinger P., Kieburtz K., McDermott M.P. The relationship between uric acid levels and Huntington's disease progression. Mov. Disord. 2010, 25:224-228.
13. Barbalat R., Ewald S.E., Mouchess M.L., Barton G.M. Nucleic acid recognition by the innate immune system. Annu. Rev. Immunol. 2011, 29:185-214.
14. Barrientos R.M., Higgins E.A., Biedenkapp J.C., Sprunger D.B., Wright-Hardesty K.J., Watkins L.R., Rudy J.W., Maier S.F. Peripheral infection and aging interact to impair hippocampal memory consolidation. Neurobiol. Aging 2006, 27:723-732.
15. Becker C.E., O'Neill L.A. Inflammasomes in inflammatory disorders: the role of TLRs and their interactions with NLRs. Semin. Immunopathol. 2007, 29:239-248.
16. Benarroch E.E. Microglia: multiple roles in surveillance, circuit shaping, and response to injury. Neurology 2013, 81:1079-1088.
17. Bianchi M.E. DAMPs, PAMPs and alarmins: all we need to know about danger. J. Leukoc. Biol. 2007, 81:1-5.
18. Broere F., van der Zee R., van Eden W. Heat shock proteins are no DAMPs, rather 'DAMPERs'. Nat. Rev. Immunol. 2011, 11:565. (Author reply 565).
19. Burns K., Janssens S., Brissoni B., Olivos N., Beyaert R., Tschopp J. Inhibition of interleukin 1 receptor/Toll-like receptor signaling through the alternatively spliced, short form of MyD88 is due to its failure to recruit IRAK-4. J. Exp. Med. 2003, 197:263-268.
20. Businaro R., Leone S., Fabrizi C., Sorci G., Donato R., Lauro G.M., Fumagalli L. S100B protects LAN-5 neuroblastoma cells against Abeta amyloid-induced neurotoxicity via RAGE engagement at low doses but increases Abeta amyloid neurotoxicity at high doses. J. Neurosci. Res. 2006, 83:897-906.
21. Cahill C.M., Lahiri D.K., Huang X., Rogers J.T. Amyloid precursor protein and alpha synuclein translation, implications for iron and inflammation in neurodegenerative diseases. Biochim. Biophys. Acta 2009, 1790:615-628.
22. Cai H., Cong W.N., Ji S., Rothman S., Maudsley S., Martin B. Metabolic dysfunction in Alzheimer's disease and related neurodegenerative disorders. Curr. Alzheimer Res. 2012, 9:5-17.
23. Campbell A. Inflammation, neurodegenerative diseases, and environmental exposures. Ann. N.Y. Acad. Sci. 2004, 1035:117-132.
24. Chakraborty S., Kaushik D.K., Gupta M., Basu A. Inflammasome signaling at the heart of central nervous system pathology. J. Neurosci. Res. 2010, 88:1615-1631.
25. Chavakis T., Bierhaus A., Al-Fakhri N., Schneider D., Witte S., Linn T., Nagashima M., Morser J., Arnold B., Preissner K.T., Nawroth P.P. The pattern recognition receptor (RAGE) is a counterreceptor for leukocyte integrins: a novel pathway for inflammatory cell recruitment. J. Exp. Med. 2003, 198:1507-1515.
26. Chaves M.L., Camozzato A.L., Ferreira E.D., Piazenski I., Kochhann R., Dall'Igna O., Mazzini G.S., Souza D.O., Portela L.V. Serum levels of S100B and NSE proteins in Alzheimer's disease patients. J. Neuroinflamm. 2010, 7:6.
27. Chen G.Y., Nunez G. Sterile inflammation: sensing and reacting to damage. Nat. Rev. Immunol. 2010, 10:826-837.
28. Chiarini A., Dal Pra I., Whitfield J.F., Armato U. The killing of neurons by beta-amyloid peptides, prions, and pro-inflammatory cytokines. Ital. J. Anat. Embryol. 2006, 111:221-246.
29. Choudhury M.E., Moritoyo T., Kubo M., Kyaw W.T., Yabe H., Nishikawa N., Nagai M., Matsuda S., Nomoto M. Zonisamide-induced long-lasting recovery of dopaminergic neurons from MPTP-toxicity. Brain Res. 2011, 1384:170-178.
30. Communi D., Janssens R., Suarez-Huerta N., Robaye B., Boeynaems J.M. Advances in signalling by extracellular nucleotides. The role and transduction mechanisms of P2Y receptors. Cell Signal. 2000, 12:351-360.
31. Czirr E., Wyss-Coray T. The immunology of neurodegeneration. J. Clin. Invest. 2012, 122:1156-1163.
32. de Rivero Vaccari J.P., Dietrich W.D., Keane R.W. Activation and regulation of cellular inflammasomes: gaps in our knowledge for central nervous system injury. J. Cereb. Blood Flow Metab. 2014, 34:369-375.
33. de Rivero Vaccari J.P., Lotocki G., Alonso O.F., Bramlett H.M., Dietrich W.D., Keane R.W. Therapeutic neutralization of the NLRP1 inflammasome reduces the innate immune response and improves histopathology after traumatic brain injury. J. Cereb. Blood Flow Metab. 2009, 29:1251-1261.
34. de Rivero Vaccari J.P., Lotocki G., Marcillo A.E., Dietrich W.D., Keane R.W. A molecular platform in neurons regulates inflammation after spinal cord injury. J. Neurosci. 2008, 28:3404-3414.
35. De Vera M., Rahman M.M., Rankin J., Kopec J., Gao X., Choi H. Gout and the risk of Parkinson's disease: a cohort study. Arthritis Rheum. 2008, 59:1549-1554.
36. Degryse B., de Virgilio M. The nuclear protein HMGB1, a new kind of chemokine?. FEBS Lett. 2003, 553:11-17.
37. Deloulme J.C., Mbele G.O., Baudier J. S100 proteins from purification to functions. Methods Mol. Biol. 2002, 172:185-198.
38. Di Bona D., Plaia A., Vasto S., Cavallone L., Lescai F., Franceschi C., Licastro F., Colonna-Romano G., Lio D., Candore G., Caruso C. Association between the interleukin-1beta polymorphisms and Alzheimer's disease: a systematic review and meta-analysis. Brain Res. Rev. 2008, 59:155-163.
39. Dinarello C.A. Immunological and inflammatory functions of the interleukin-1 family. Annu. Rev. Immunol. 2009, 27:519-550.
40. Donato R., Cannon B.R., Sorci G., Riuzzi F., Hsu K., Weber D.J., Geczy C.L. Functions of S100 proteins. Curr. Mol. Med. 2013, 13:24-57.
41. Donato R., Sorci G., Riuzzi F., Arcuri C., Bianchi R., Brozzi F., Tubaro C., Giambanco I. S100B's double life: intracellular regulator and extracellular signal. Biochim. Biophys. Acta 2009, 1793:1008-1022.
42. Eckle T., Fullbier L., Wehrmann M., Khoury J., Mittelbronn M., Ibla J., Rosenberger P., Eltzschig H.K. Identification of ectonucleotidases CD39 and CD73 in innate protection during acute lung injury. J. Immunol. 2007, 178:8127-8137.
43. Ellinger J., Muller D.C., Muller S.C., Hauser S., Heukamp L.C., von Ruecker A., Bastian P.J., Walgenbach-Brunagel G. Circulating mitochondrial DNA in serum: a universal diagnostic biomarker for patients with urological malignancies. Urol. Oncol. 2012, 30:509-515.
44. Erlandsson Harris H., Andersson U. Mini-review: the nuclear protein HMGB1 as a proinflammatory mediator. Eur. J. Immunol. 2004, 34:1503-1512.
45. Esposito G., Scuderi C., Lu J., Savani C., De Filippis D., Iuvone T., Steardo L., Sheen V., Steardo L. S100B induces tau protein hyperphosphorylation via Dickopff-1 up-regulation and disrupts the Wnt pathway in human neural stem cells. J. Cell Mol. Med. 2008, 12:914-927.
46. Fang P., Schachner M., Shen Y.Q. HMGB1 in development and diseases of the central nervous system. Mol. Neurobiol. 2012, 45:499-506.
47. Fernandes-Alnemri T., Alnemri E.S. Assembly, purification, and assay of the activity of the ASC pyroptosome. Methods Enzymol. 2008, 442:251-270.
48. Fernandes-Alnemri T., Wu J., Yu J.W., Datta P., Miller B., Jankowski W., Rosenberg S., Zhang J., Alnemri E.S. The pyroptosome: a supramolecular assembly of ASC dimers mediating inflammatory cell death via caspase-1 activation. Cell Death Differ. 2007, 14:1590-1604.
49. Ferrari D., Pizzirani C., Adinolfi E., Lemoli R.M., Curti A., Idzko M., Panther E., Di Virgilio F. The P2X7 receptor: a key player in IL-1 processing and release. J. Immunol. 2006, 176:3877-3883.
50. Forman M.S., Trojanowski J.Q., Lee V.M. Neurodegenerative diseases: a decade of discoveries paves the way for therapeutic breakthroughs. Nat. Med. 2004, 10:1055-1063.
51. Fossati S., Chiarugi A. Relevance of high-mobility group protein box 1 to neurodegeneration. Int. Rev. Neurobiol. 2007, 82:137-148.
52. Freche B., Reig N., van der Goot F.G. The role of the inflammasome in cellular responses to toxins and bacterial effectors. Semin. Immunopathol. 2007, 29:249-260.
53. Friedlander R.M. Apoptosis and caspases in neurodegenerative diseases. N. Engl. J. Med. 2003, 348:1365-1375.
54. Ganter M.T., Ware L.B., Howard M., Roux J., Gartland B., Matthay M.A., Fleshner M., Pittet J.F. Extracellular heat shock protein 72 is a marker of the stress protein response in acute lung injury. Am. J. Physiol. Lung Cell. Mol. Physiol. 2006, 291:L354-L361.
55. Gao H.M., Hong J.S. Why neurodegenerative diseases are progressive: uncontrolled inflammation drives disease progression. Trends Immunol. 2008, 29:357-365.
56. Gao H.M., Zhang F., Zhou H., Kam W., Wilson B., Hong J.S. Neuroinflammation and alpha-synuclein dysfunction potentiate each other, driving chronic progression of neurodegeneration in a mouse model of Parkinson's disease. Environ. Health Perspect. 2011, 119:807-814.
57. Gao H.M., Zhou H., Zhang F., Wilson B.C., Kam W., Hong J.S. HMGB1 acts on microglia Mac1 to mediate chronic neuroinflammation that drives progressive neurodegeneration. J. Neurosci. 2011, 31:1081-1092.
58. Gardella S., Andrei C., Ferrera D., Lotti L.V., Torrisi M.R., Bianchi M.E., Rubartelli A. The nuclear protein HMGB1 is secreted by monocytes via a non-classical, vesicle-mediated secretory pathway. EMBO Rep. 2002, 3:995-1001.
59. Gelain D.P., Augusto M.A.P., Clarissa M.C., Sartori G.M., Cristiane R., Damiani T.C., Cascaes A.C., Joao Q., Felipe D., Fonseca M.J. Serum heat shock protein 70 levels, oxidant status, and mortality in sepsis. Shock 2011, 35:466-470.
60. Giuliano J.S., Lahni P.M., Wong H.R., Wheeler D.S. Pediatric sepsis-Part V: Extracellular heat shock proteins: alarmins for the host immune system. Open Inflamm. J. 2011, 4:49-60.
61. Giunta S. Is inflammaging an auto[innate]immunity subclinical syndrome?. Immun. Ageing: IA 2006, 3:12.
62. Golde T.E., Borchelt D.R., Giasson B.I., Lewis J. Thinking laterally about neurodegenerative proteinopathies. J. Clin. Invest. 2013, 123:1847-1855.
63. Gorman A.M. Neuronal cell death in neurodegenerative diseases: recurring themes around protein handling. J. Cell. Mol. Med. 2008, 12:2263-2280.
64. Griffin W.S. Inflammation and neurodegenerative diseases. Am. J. Clin. Nutr. 2006, 83:470S-474S.
65. Habich C., Kempe K., van der Zee R., Rumenapf R., Akiyama H., Kolb H., Burkart V. Heat shock protein 60: specific binding of lipopolysaccharide. J. Immunol. 2005, 174:1298-1305.
66. Halle A., Hornung V., Petzold G.C., Stewart C.R., Monks B.G., Reinheckel T., Fitzgerald K.A., Latz E., Moore K.J., Golenbock D.T. The NALP3 inflammasome is involved in the innate immune response to amyloid-beta. Nat. Immunol. 2008, 9:857-865.
67. Harris H.E., Raucci A. Alarmin(g) news about danger: workshop on innate danger signals and HMGB1. EMBO Rep. 2006, 7:774-778.
68. Hauser C.J., Sursal T., Rodriguez E.K., Appleton P.T., Zhang Q., Itagaki K. Mitochondrial damage associated molecular patterns from femoral reamings activate neutrophils through formyl peptide receptors and P44/42 MAP kinase. J. Orthopaed. Trauma 2010, 24:534-538.
69. Heizmann C.W., Fritz G., Schafer B.W. S100 proteins: structure, functions and pathology. Front. Biosci. 2002, 7:d1356-d1368.
70. Heneka M.T., Kummer M.P., Stutz A., Delekate A., Schwartz S., Vieira-Saecker A., Griep A., Axt D., Remus A., Tzeng T.C., Gelpi E., Halle A., Korte M., Latz E., Golenbock D.T. NLRP3 is activated in Alzheimer's disease and contributes to pathology in APP/PS1 mice. Nature 2013, 493:674-678.
71. Heneka M.T., O'Banion M.K. Inflammatory processes in Alzheimer's disease. J. Neuroimmunol. 2007, 184:69-91.
72. Hohlfeld R., Kerschensteiner M., Meinl E. Dual role of inflammation in CNS disease. Neurology 2007, 68:S58-S63. (Discussion S91-56).
73. Jang A., Liew H., Kim Y.M., Choi H., Kim S., Lee S.H., Ohshima T., Mikoshiba K., Suh Y.H. p35 deficiency accelerates HMGB-1-mediated neuronal death in the early stages of an Alzheimer's disease mouse model. Curr. Alzheimer Res. 2013, 10:829-843.
74. Jin M., Yang F., Yang I., Yin Y., Luo J.J., Wang H., Yang X.F. Uric acid, hyperuricemia and vascular diseases. Front. Biosci. 2012, 17:656-669.
75. Jounai N., Kobiyama K., Takeshita F., Ishii K.J. Recognition of damage-associated molecular patterns related to nucleic acids during inflammation and vaccination. Front. Cell. Infect. Microbiol. 2012, 2:168.
76. Jylhava J., Jylha M., Lehtimaki T., Hervonen A., Hurme M. Circulating cell-free DNA is associated with mortality and inflammatory markers in nonagenarians: the Vitality 90+ study. Exp. Gerontol. 2012, 47:372-378.
77. Jylhava J., Kotipelto T., Raitala A., Jylha M., Hervonen A., Hurme M. Aging is associated with quantitative and qualitative changes in circulating cell-free DNA: the Vitality 90+ study. Mech. Ageing Dev. 2011, 132:20-26.
78. Jylhava J., Nevalainen T., Marttila S., Jylha M., Hervonen A., Hurme M. Characterization of the role of distinct plasma cell-free DNA species in age-associated inflammation and frailty. Aging Cell 2013, 12:388-397.
79. Kanneganti T.D., Ozoren N., Body-Malapel M., Amer A., Park J.H., Franchi L., Whitfield J., Barchet W., Colonna M., Vandenabeele P., Bertin J., Coyle A., Grant E.P., Akira S., Nunez G. Bacterial RNA and small antiviral compounds activate caspase-1 through cryopyrin/Nalp3. Nature 2006, 440:233-236.
80. Kleindienst A., McGinn M.J., Harvey H.B., Colello R.J., Hamm R.J., Bullock M.R. Enhanced hippocampal neurogenesis by intraventricular S100B infusion is associated with improved cognitive recovery after traumatic brain injury. J. Neurotrauma 2005, 22:645-655.
81. Kohler C., Radpour R., Barekati Z., Asadollahi R., Bitzer J., Wight E., Burki N., Diesch C., Holzgreve W., Zhong X.Y. Levels of plasma circulating cell free nuclear and mitochondrial DNA as potential biomarkers for breast tumors. Mol. Cancer 2009, 8:105.
82. Koprich J.B., Reske-Nielsen C., Mithal P., Isacson O. Neuroinflammation mediated by IL-1beta increases susceptibility of dopamine neurons to degeneration in an animal model of Parkinson's disease. J. Neuroinflamm. 2008, 5:8.
83. Kutzing M.K., Firestein B.L. Altered uric acid levels and disease states. J. Pharmacol. Exp. Ther. 2008, 324:1-7.
84. Lambert J.C., Ferreira S., Gussekloo J., Christiansen L., Brysbaert G., Slagboom E., Cottel D., Petit T., Hauw J.J., DeKosky S.T., Richard F., Berr C., Lendon C., Kamboh M.I., Mann D., Christensen K., Westendorp R., Amouyel P. Evidence for the association of the S100beta gene with low cognitive performance and dementia in the elderly. Mol. Psychiatry 2007, 12:870-880.
85. Lamkanfi M., Dixit V.M. The inflammasomes. PLoS Pathog. 2009, 5:e1000510.
86. Lamkanfi M., Vande Walle L., Kanneganti T.D. Deregulated inflammasome signaling in disease. Immunol. Rev. 2011, 243:163-173.
87. Land W.G., Messmer K. The danger theory in view of the injury hypothesis: 20 years later. Front. Immunol. 2012, 3:349.
88. Lechan R.M., Toni R., Clark B.D., Cannon J.G., Shaw A.R., Dinarello C.A., Reichlin S. Immunoreactive interleukin-1 beta localization in the rat forebrain. Brain Res. 1990, 514:135-140.
89. Lindersson E.K., Hojrup P., Gai W.P., Locker D., Martin D., Jensen P.H. alpha-Synuclein filaments bind the transcriptional regulator HMGB-1. NeuroReport 2004, 15:2735-2739.
90. Liu-Bryan R., Pritzker K., Firestein G.S., Terkeltaub R. TLR2 signaling in chondrocytes drives calcium pyrophosphate dihydrate and monosodium urate crystal-induced nitric oxide generation. J. Immunol. 2005, 174:5016-5023.
91. Liu-Bryan R., Scott P., Sydlaske A., Rose D.M., Terkeltaub R. Innate immunity conferred by Toll-like receptors 2 and 4 and myeloid differentiation factor 88 expression is pivotal to monosodium urate monohydrate crystal-induced inflammation. Arthritis Rheum. 2005, 52:2936-2946.
92. Liu B., Hong J.S. Role of microglia in inflammation-mediated neurodegenerative diseases: mechanisms and strategies for therapeutic intervention. J. Pharmacol. Exp. Ther. 2003, 304:1-7.
93. LoCicero J., Xu X., Zhang L. Heat shock protein suppresses the senescent lung cytokine response to acute endotoxemia. Ann. Thorac. Surg. 1999, 68:1150-1153.
94. Lotze M.T., Tracey K.J. High-mobility group box 1 protein (HMGB1): nuclear weapon in the immune arsenal. Nat. Rev. Immunol. 2005, 5:331-342.
95. Lue L.F., Rydel R., Brigham E.F., Yang L.B., Hampel H., Murphy G.M., Brachova L., Yan S.D., Walker D.G., Shen Y., Rogers J. Inflammatory repertoire of Alzheimer's disease and nondemented elderly microglia in vitro. Glia 2001, 35:72-79.
96. Manfredi A.A., Rovere-Querini P. The mitochondrion-a Trojan horse that kicks off inflammation. N. Engl. J. Med. 2010, 362:2132-2134.
97. Martinon F., Mayor A., Tschopp J. The inflammasomes: guardians of the body. Annu. Rev. Immunol. 2009, 27:229-265.
98. Martinon F., Petrilli V., Mayor A., Tardivel A., Tschopp J. Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature 2006, 440:237-241.
99. Mathew A., Lindsley T.A., Sheridan A., Bhoiwala D.L., Hushmendy S.F., Yager E.J., Ruggiero E.A., Crawford D.R. Degraded mitochondrial DNA is a newly identified subtype of the damage associated molecular pattern (DAMP) family and possible trigger of neurodegeneration. J. Alzheimers Dis. 2012, 30:617-627.
100. Matzinger P. Tolerance, danger, and the extended family. Annu. Rev. Immunol. 1994, 12:991-1045.
101. Matzinger P. An innate sense of danger. Semin. Immunol. 1998, 10:399-415.
102. Matzinger P. An innate sense of danger. Ann. N.Y. Acad. Sci. 2002, 961:341-342.
103. Mawhinney L.J., de Rivero Vaccari J.P., Dale G.A., Keane R.W., Bramlett H.M. Heightened inflammasome activation is linked to age-related cognitive impairment in Fischer 344 rats. BMC Neurosci. 2011, 12:123.
104. Mazarati A., Maroso M., Iori V., Vezzani A., Carli M. High-mobility group box-1 impairs memory in mice through both toll-like receptor 4 and receptor for advanced glycation end products. Exp. Neurol. 2011, 232:143-148.
105. McRae A., Dahlstrom A. Immune responses in brains of Alzheimer's and Parkinson's disease patients: hypothesis and reality. Rev. Neurosci. 1992, 3:79-98.
106. Menu P., Vince J.E. The NLRP3 inflammasome in health and disease: the good, the bad and the ugly. Clin. Exp. Immunol. 2011, 166:1-15.
107. Min H.J., Ko E.A., Wu J., Kim E.S., Kwon M.K., Kwak M.S., Choi J.E., Lee J.E., Shin J.S. Chaperone-like activity of high-mobility group box 1 protein and its role in reducing the formation of polyglutamine aggregates. J. Immunol. 2013, 190:1797-1806.
108. Minghetti L. Role of inflammation in neurodegenerative diseases. Curr. Opin. Neurol. 2005, 18:315-321.
109. Mori T., Koyama N., Arendash G.W., Horikoshi-Sakuraba Y., Tan J., Town T. Overexpression of human S100B exacerbates cerebral amyloidosis and gliosis in the Tg2576 mouse model of Alzheimer's disease. Glia 2010, 58:300-314.
110. Mori T., Town T., Tan J., Yada N., Horikoshi Y., Yamamoto J., Shimoda T., Kamanaka Y., Tateishi N., Asano T. Arundic acid ameliorates cerebral amyloidosis and gliosis in Alzheimer transgenic mice. J. Pharmacol. Exp. Ther. 2006, 318:571-578.
111. Noyan-Ashraf M.H., Sadeghinejad Z., Juurlink B.H. Dietary approach to decrease aging-related CNS inflammation. Nutr. Neurosci. 2005, 8:101-110.
112. Okun E., Griffioen K.J., Lathia J.D., Tang S.C., Mattson M.P., Arumugam T.V. Toll-like receptors in neurodegeneration. Brain Res. Rev. 2009, 59:278-292.
113. Osterloh A., Kalinke U., Weiss S., Fleischer B., Breloer M. Synergistic and differential modulation of immune responses by Hsp60 and lipopolysaccharide. J. Biol. Chem. 2007, 282:4669-4680.
114. Pan Y., Chen X.Y., Zhang Q.Y., Kong L.D. Microglial NLRP3 inflammasome activation mediates IL-1beta-related inflammation in prefrontal cortex of depressive rats. Brain Behav. Immun. 2014, 40:90-100.
115. Pelegrin P., Surprenant A. Pannexin-1 couples to maitotoxin- and nigericin-induced interleukin-1beta release through a dye uptake-independent pathway. J. Biol. Chem. 2007, 282:2386-2394.
116. Pinti M., Cevenini E., Nasi M., De Biasi S., Salvioli S., Monti D., Benatti S., Gibellini L., Cotichini R., Stazi M.A., Trenti T., Franceschi C., Cossarizza A. Circulating mitochondrial DNA increases with age and is a familiar trait: implications for inflamm-aging. Eur. J. Immunol. 2014, 44:1552-1562.
117. Proell M., Gerlic M., Mace P.D., Reed J.C., Riedl S.J. The CARD plays a critical role in ASC foci formation and inflammasome signalling. Biochem. J. 2013, 449:613-621.
118. Pyle A., Burn D.J., Gordon C., Swan C., Chinnery P.F., Baudouin S.V. Fall in circulating mononuclear cell mitochondrial DNA content in human sepsis. Intensive Care Med. 2010, 36:956-962.
119. Qi M.L., Tagawa K., Enokido Y., Yoshimura N., Wada Y., Watase K., Ishiura S., Kanazawa I., Botas J., Saitoe M., Wanker E.E., Okazawa H. Proteome analysis of soluble nuclear proteins reveals that HMGB1/2 suppress genotoxic stress in polyglutamine diseases. Nat. Cell Biol. 2007, 9:402-414.
120. Ramasamy R., Yan S.F., Schmidt A.M. RAGE: therapeutic target and biomarker of the inflammatory response-the evidence mounts. J. Leukocyte Biol. 2009, 86:505-512.
121. Roltsch E., Holcomb L., Young K.A., Marks A., Zimmer D.B. PSAPP mice exhibit regionally selective reductions in gliosis and plaque deposition in response to S100B ablation. J. Neuroinflamm. 2010, 7:78.
122. Romanos E., Planas A.M., Amaro S., Chamorro A. Uric acid reduces brain damage and improves the benefits of rt-PA in a rat model of thromboembolic stroke. J. Cereb. Blood Flow Metab. 2007, 27:14-20.
123. Sathe K., Maetzler W., Lang J.D., Mounsey R.B., Fleckenstein C., Martin H.L., Schulte C., Mustafa S., Synofzik M., Vukovic Z., Itohara S., Berg D., Teismann P. S100B is increased in Parkinson's disease and ablation protects against MPTP-induced toxicity through the RAGE and TNF-alpha pathway. Brain 2012, 135:3336-3347.
124. Schafer B.W., Heizmann C.W. The S100 family of EF-hand calcium-binding proteins: functions and pathology. Trends Biochem. Sci. 1996, 21:134-140.
125. Song J.X., Lu J.H., Liu L.F., Chen L.L., Durairajan S.S., Yue Z., Zhang H.Q., Li M. HMGB1 is involved in autophagy inhibition caused by SNCA/alpha-synuclein overexpression: a process modulated by the natural autophagy inducer corynoxine B. Autophagy 2014, 10:144-154.
126. Sorci G., Bianchi R., Riuzzi F., Tubaro C., Arcuri C., Giambanco I., Donato R. S100B protein, a damage-associated molecular pattern protein in the brain and heart, and beyond. Cardiovasc. Psychiatry Neurol 2010, 2010, pii: 656481.
127. Sorci G., Giovannini G., Riuzzi F., Bonifazi P., Zelante T., Zagarella S., Bistoni F., Donato R., Romani L. The danger signal S100B integrates pathogen- and danger-sensing pathways to restrain inflammation. PLoS Pathog. 2011, 7:e1001315.
128. Stetler R.A., Gan Y., Zhang W., Liou A.K., Gao Y., Cao G., Chen J. Heat shock proteins: cellular and molecular mechanisms in the central nervous system. Prog. Neurobiol. 2010, 92:184-211.
129. Su X., Federoff H.J. Immune responses in Parkinson's disease: interplay between central and peripheral immune systems. BioMed. Res. Int. 2014, 2014:275178.
130. Sun N.K., Chao C.C. The cytokine activity of HMGB1-extracellular escape of the nuclear protein. Chang Gung Med. J. 2005, 28:673-682.
131. Takata K., Kitamura Y., Tsuchiya D., Kawasaki T., Taniguchi T., Shimohama S. High mobility group box protein-1 inhibits microglial abeta clearance and enhances abeta neurotoxicity. J. Neurosci. Res. 2004, 78:880-891.
132. Tan M.S., Yu J.T., Jiang T., Zhu X.C., Tan L. The NLRP3 inflammasome in Alzheimer's disease. Mol. Neurobiol. 2013, 48:875-882.
133. Tang D., Kang R., Coyne C.B., Zeh H.J., Lotze M.T. PAMPs and DAMPs: signal 0s that spur autophagy and immunity. Immunol. Rev. 2012, 249:158-175.
134. Tang D., Kang R., Livesey K.M., Cheh C.W., Farkas A., Loughran P., Hoppe G., Bianchi M.E., Tracey K.J., Zeh H.J., Lotze M.T. Endogenous HMGB1 regulates autophagy. J. Cell Biol. 2010, 190:881-892.
135. Ting J.P., Lovering R.C., Alnemri E.S., Bertin J., Boss J.M., Davis B.K., Flavell R.A., Girardin S.E., Godzik A., Harton J.A., Hoffman H.M., Hugot J.P., Inohara N., Mackenzie A., Maltais L.J., Nunez G., Ogura Y., Otten L.A., Philpott D., Reed J.C., Reith W., Schreiber S., Steimle V., Ward P.A. The NLR gene family: a standard nomenclature. Immunity 2008, 28:285-287.
136. Huang T., Gong L., Luo W., Hu L., Liu C. Protective effect of uric acid against 6-OHDA-induced injury in SH-SY5Y cells. Mol. Neurodegener. 2012, 7(Suppl 1):S12.
137. Ulloa L., Messmer D. High-mobility group box 1 (HMGB1) protein: friend and foe. Cytokine Growth Factor Rev. 2006, 17:189-201.
138. Vajjhala P.R., Mirams R.E., Hill J.M. Multiple binding sites on the pyrin domain of ASC protein allow self-association and interaction with NLRP3 protein. J. Biol. Chem. 2012, 287:41732-41743.
139. van Eden W., Spiering R., Broere F., van der Zee R. A case of mistaken identity: HSPs are no DAMPs but DAMPERs. Cell Stress Chaperones 2012, 17:281-292.
140. Van Eldik L.J., Griffin W.S. S100 beta expression in Alzheimer's disease: relation to neuropathology in brain regions. Biochim. Biophys. Acta 1994, 1223:398-403.
141. Van Eldik L.J., Wainwright M.S. The Janus face of glial-derived S100B: beneficial and detrimental functions in the brain. Restor. Neurol. Neurosci. 2003, 21:97-108.
142. Warger T., Hilf N., Rechtsteiner G., Haselmayer P., Carrick D.M., Jonuleit H., von Landenberg P., Rammensee H.G., Nicchitta C.V., Radsak M.P., Schild H. Interaction of TLR2 and TLR4 ligands with the N-terminal domain of Gp96 amplifies innate and adaptive immune responses. J. Biol. Chem. 2006, 281:22545-22553.
143. Wilms H., Zecca L., Rosenstiel P., Sievers J., Deuschl G., Lucius R. Inflammation in Parkinson's diseases and other neurodegenerative diseases: cause and therapeutic implications. Curr. Pharm. Des. 2007, 13:1925-1928.
144. Wofford J.L., Loehr L.R., Schwartz E. Acute cognitive impairment in elderly ED patients: etiologies and outcomes. Am. J. Emerg. Med. 1996, 14:649-653.
145. Zhang J., Niu N., Li B., McNutt M.A. Neuron-derived IgG protects neurons from complement-dependent cytotoxicity. J. Histochem. Cytochem. 2013, 61:869-879.
146. Zhang J., Niu N., Wang M., McNutt M.A., Zhang D., Zhang B., Lu S., Liu Y., Liu Z. Neuron-derived IgG protects dopaminergic neurons from insult by 6-OHDA and activates microglia through the FcgammaR I and TLR4 pathways. Int. J. Biochem. Cell Biol. 2013, 45:1911-1920.
147. Zhang Q., Itagaki K., Hauser C.J. Mitochondrial DNA is released by shock and activates neutrophils via p38 map kinase. Shock 2010, 34:55-59.
148. Zhang Q., Raoof M., Chen Y., Sumi Y., Sursal T., Junger W., Brohi K., Itagaki K., Hauser C.J. Circulating mitochondrial DAMPs cause inflammatory responses to injury. Nature 2010, 464:104-107.
149. Zheng Q. Editorial: skin inflammation and inflammaging. Inflamm. Allergy Drug Targets 2014, 13:151-152.
150. Zheng Q., Ren Y., Reinach P.S., She Y., Xiao B., Hua S., Qu J., Chen W. Reactive oxygen species activated NLRP3 inflammasomes prime environment-induced murine dry eye. Exp. Eye Res. 2014, 125C:1-8.
151. Zipp F., Aktas O. The brain as a target of inflammation: common pathways link inflammatory and neurodegenerative diseases. Trends Neurosci. 2006, 29:518-527.